Global Cystic Fibrosis (CF) Drugs Market US$ 5.2 Billion by 2021

The global cystic fibrosis (CF) drugs market expected to reach US$ 5.2 billion by 2021, growing at CAGR 14.9% over the forecast period 2017-2021.
The CF treatment options include: airway-clearance techniques and medications to clear mucus from the lungs; proactive treatment of infections; pancreatic enzyme replacement therapy (PERT); optimal nutrition; and an active lifestyle. Ivacaftor (Kalydeco) was the first drug approved by the US Food and Drug Administration (FDA) in 2012, however it remains very expensive.

Visit the global cystic fibrosis drugs market by drug class – anti-infectives, CF transmembrane conductance regulator (CFTR) modulators, mucolytics, and pancreatic enzyme replacement therapy (PERT), by geography and forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/

The global cystic fibrosis drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global cystic fibrosis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global cystic fibrosis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global cystic fibrosis drugs market and profiled in this report include AbbVie, AlgiPharma, Aptalis Pharma, Cystic Fibrosis Foundation (CFF), Eli Lilly, Genentech (Roche), Grifols, Insmed, KaloBios Pharmaceuticals, N30 Pharmaceuticals, NovaBiotics, Novartis, Pharmaxis, PTC Therapeutics, Savara Pharmaceuticals, UK Cystic Fibrosis Gene Therapy Consortium (CFGTC), and Vertex Pharmaceuticals.

1. Drug Class
1.1. Anti-infectives
1.2. CF Transmembrane Conductance Regulator (CFTR) modulators
1.3. Mucolytics
1.4. Pancreatic Enzyme Replacement Therapy (PERT)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. AbbVie
3.2. AlgiPharma
3.3. Aptalis Pharma
3.4. Cystic Fibrosis Foundation (CFF)
3.5. Eli Lilly
3.6. Genentech (Roche)
3.7. Grifols
3.8. Insmed
3.9. KaloBios Pharmaceuticals
3.10. N30 Pharmaceuticals
3.11. NovaBiotics
3.12. Novartis
3.13. Pharmaxis
3.14. PTC Therapeutics
3.15. Savara Pharmaceuticals
3.16. UK Cystic Fibrosis Gene Therapy Consortium (CFGTC)
3.17. Vertex Pharmaceuticals

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.